A report on transmissible spongiform encephalopathies and transfusion safety

被引：12

作者：

Coste, J. ^{[1
]}

Prowse, C. ^{[2
]}

Eglin, R. ^{[3
]}

Fang, C. ^{[4
]}

机构：

[1] Etab Francais Sang Pyrenees Mediterranee, F-34094 Montpellier 5, France

[2] Scottish Natl Blood Transfus Serv, Edinburgh, Midlothian, Scotland

[3] Colindale Ctr, Natl Hlth Serv Blood & Tissues, Natl Transfus Microbiol Lab, London, England

[4] Amer Red Cross, Transmissible Dis Dept, Biomed Res & Dev, Rockville, MD USA

来源：

VOX SANGUINIS | 2009年 / 96卷 / 04期

关键词：

Prion; transmissible spongiform encephalopathies; transfusion safety; prion detection; prion removal; CREUTZFELDT-JAKOB-DISEASE; BLOOD-TRANSFUSION; PRION PROTEIN; EXPERIMENTAL-MODEL; HAMSTER BLOOD; VARIANT; SCRAPIE; VCJD; INFECTIVITY; AMPLIFICATION;

D O I：

10.1111/j.1423-0410.2009.01161.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incidence of BSE in Europe is in continued decline. At present, iatrogenic transmission from person to person is considered a serious threat to public health. This report of the International Society of Blood Transfusion Working Party on Transmissible Spongiform Encephalopathy will focus on the state of the art in relation to blood components and plasma safety. Latest information on the pathogenicity of the infectious agent, the frequency and dynamics of infection in blood and transfusion transmissibility will be documented. Preventive measures including donor deferral policies, technologies for prion removal from labile blood components and for prion detection in plasma, the absence of a sensitive and rapid reference assay able to confirm the positive results from any putative blood screening assay will be updated. At last, as many uncertainties remain and a number of assumptions await confirmation, the areas to continue to explore are listed.

引用

页码：284 / 291

页数：8

共 46 条

[11] vCJD and blood transfusion: risk assessment in the United Kingdom
Dobra, S. A.
Bennett, P. G.
[J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2006, 13 (05) : 307 - 311
[12] Dorsey KA, 2006, VOX SANG, V91, P68
[13] EGLIN R, 2009, NEUROPRION 0926
[14] Selection of spiking materials for studies on the clearance of agents of transmissible spongiform encephalopathy during plasma fractionation
Foster, Peter R.
[J]. BIOLOGICALS, 2008, 36 (02) : 142 - 143
[15] Prions and blood products
Foster, PR
[J]. ANNALS OF MEDICINE, 2000, 32 (07) : 501 - 513
[16] Commentary: Predicting the unpredictable: the future incidence of variant Creutzfeldt-Jakob disease
Ghani, AC
[J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2003, 32 (05) : 792 - 793
[17] Gregori L, 2007, DEV BIOLOGICALS, V127, P123
[18] Hagiwara K, 2007, JPN J INFECT DIS, V60, P305
[19] vCJD and blood transfusion in the United Kingdom
Hewitt, P.
[J]. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2006, 13 (05) : 312 - 316
[20] Creutzfeldt-Jakob disease and blood transfusion: Results of the UK transfusion medicine epidemiological review study
Hewitt, P. E.
Llewelyn, C. A.
Mackenzie, J.
Will, R. G.
[J]. VOX SANGUINIS, 2006, 91 (03) : 221 - 230

← 1 2 3 4 5 →